Replies to post #732854 on NorthWest Biotherapeutics Inc (NWBO)

[theorysuit]

It s one of the two approved fda autologous cell therapies this year. It has several other pivotal rmat trials in other indications under way. Firing on all cylinders. Check back on this one in a year or two. Nwbo should take notes on how execution is done there.

[dstock07734]

Horse,

First by all means, read the following paper which is about basically DCVax-L + KLH with/without CYT107 on three tough tumors of cold type. Tumor lysate was prepared mostly from tissues extracted by biopsy needle. All the patients had cancer either metastasized or recurrent. Over 30% of patients were cancer free five years after the treatment.

https://aacrjournals.org/clincancerres/article/22/13/3182/79179/Adjuvant-Immunotherapy-to-Improve-Outcome-in-High

As for Lifileucel, IMO, the only significance as cell therapy is that it makes DCVax-L more outstanding. The following was taken from the paper on Lifileucel. Patients have to go through a procedure that has their immune system wiped out before going through the treatment. The interesting part is that the neoadjuvant treatment as shown in the NADINA has extraordinary efficacy which will significantly reduce the number of patients who have to resort to Lifileucel.

Patients received a non-myeloablative lymphodepletion regimen, a single lifileucel infusion, and up to six doses of high-dose interleukin- 2.

https://www.iovance.com/uploads/Chesney-JITC-2022-Efficacy-and-safety-of-lifileucel-TIL-cell-therapy-in-pts-w-adv-melanoma-after-pr-2447-publication.pdf

Neoadjuvant treatment

https://www.nejm.org/doi/full/10.1056/NEJMoa2402604